What is HC Wainwright’s Estimate for SGMO FY2026 Earnings?

Sangamo Therapeutics, Inc. (NASDAQ:SGMO) – Equities research analysts at HC Wainwright reduced their FY2026 earnings per share (EPS) estimates for Sangamo Therapeutics in a report issued on Tuesday, May 26th. HC Wainwright analyst P. Trucchio now forecasts that the biopharmaceutical company will post earnings per share of ($0.20) for the year, down from their previous forecast of ($0.17). HC Wainwright currently has a “Buy” rating and a $10.00 target price on the stock. The consensus estimate for Sangamo Therapeutics’ current full-year earnings is ($0.17) per share. HC Wainwright also issued estimates for Sangamo Therapeutics’ Q4 2026 earnings at ($0.05) EPS, FY2027 earnings at ($0.05) EPS, FY2028 earnings at $0.14 EPS, FY2029 earnings at $0.25 EPS and FY2030 earnings at $0.35 EPS.

Several other equities analysts also recently weighed in on SGMO. Zacks Research downgraded Sangamo Therapeutics from a “hold” rating to a “strong sell” rating in a report on Thursday, April 16th. Wall Street Zen downgraded Sangamo Therapeutics to a “strong sell” rating in a report on Saturday, January 31st. One equities research analyst has rated the stock with a Buy rating, one has assigned a Hold rating and two have given a Sell rating to the company’s stock. According to MarketBeat, the stock presently has a consensus rating of “Reduce” and a consensus price target of $5.50.

Sangamo Therapeutics Price Performance

Shares of NASDAQ:SGMO opened at $0.20 on Thursday. Sangamo Therapeutics has a 1-year low of $0.10 and a 1-year high of $0.77. The business has a fifty day moving average price of $0.23 and a 200-day moving average price of $0.36. The company has a market capitalization of $82.86 million, a PE ratio of -0.45 and a beta of 1.04.

Insider Buying and Selling

In related news, SVP Nathalie Dubois-Stringfellow sold 345,942 shares of Sangamo Therapeutics stock in a transaction dated Tuesday, April 21st. The stock was sold at an average price of $0.26, for a total value of $89,944.92. Following the completion of the sale, the senior vice president directly owned 332,769 shares in the company, valued at approximately $86,519.94. This trade represents a 50.97% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Insiders own 4.10% of the company’s stock.

Institutional Investors Weigh In On Sangamo Therapeutics

A number of large investors have recently made changes to their positions in SGMO. Geode Capital Management LLC grew its stake in shares of Sangamo Therapeutics by 2.1% during the 2nd quarter. Geode Capital Management LLC now owns 2,332,279 shares of the biopharmaceutical company’s stock valued at $1,263,000 after purchasing an additional 48,829 shares during the period. XTX Topco Ltd bought a new stake in shares of Sangamo Therapeutics during the 2nd quarter valued at about $41,000. Invesco Ltd. grew its stake in shares of Sangamo Therapeutics by 40.6% during the 2nd quarter. Invesco Ltd. now owns 680,452 shares of the biopharmaceutical company’s stock valued at $368,000 after purchasing an additional 196,558 shares during the period. Engineers Gate Manager LP grew its stake in shares of Sangamo Therapeutics by 101.7% during the 2nd quarter. Engineers Gate Manager LP now owns 87,425 shares of the biopharmaceutical company’s stock valued at $47,000 after purchasing an additional 44,078 shares during the period. Finally, Wasatch Advisors LP grew its stake in shares of Sangamo Therapeutics by 17.7% during the 2nd quarter. Wasatch Advisors LP now owns 8,084,419 shares of the biopharmaceutical company’s stock valued at $4,376,000 after purchasing an additional 1,215,653 shares during the period. 56.92% of the stock is currently owned by institutional investors.

Sangamo Therapeutics Company Profile

Sangamo Therapeutics, Inc is a clinical-stage biotechnology company headquartered in Brisbane, California, that specializes in the development of genomic therapies based on its proprietary zinc finger nuclease (ZFN) technology. Founded in 1995, Sangamo pioneered ZFN-based genome editing to precisely alter DNA sequences for the treatment of serious genetic and rare diseases. The company’s platform encompasses in vivo genome editing, ex vivo cell therapy, and genome regulation approaches, with a focus on durable therapeutic effects through permanent genetic modification or sustained gene expression control.

Through its genome editing programs, Sangamo is advancing multiple product candidates into clinical trials for conditions such as hemophilia A and B, mucopolysaccharidosis types I and II, and lysosomal storage disorders.